FDA Approval Activities for this Drug…

Novantrone (mitoxantrone for Injection Concentrate), Serono, NDA 19-297/S25, S26 & S27 1/13/03 1/23/03 Novantrone (mitoxantrone for Injection Concentrate), Immunex NDA 19-297/S-024 2/20/02 2/21/02 Novantrone (mitoxantrone for Injection Concentrate), Immunex NDA 19-297/S-021 2/04/00 6/4/01 Novantrone (mitoxantrone hydrochloride) Injection,Rx Immunex NDA 21-120 10/13/00 Novantrone Indications: reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis. Mitoxantrone Injection, Bedford Laboratories, Mitoxantrone Injection, Mayne Pharma | Novantrone (mitoxantrone concentrate) injection, Serono, Labeling Revision

For the latest approval information, please locate this drug using this index.